Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07263776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2

Study acronym: IRIS-2
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Study completion pushed from Sep 16, 2026 to Jun 11, 2027 Show 4 more changesShow less
    • Primary completion date changed from estimate of Sep 16, 2026 to Sep 18, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 10 entries
    • Site details revised at 27 of 54 sites
  3. Secondary endpoints: details revised at 5 of 10 entriesv6
  4. Trial status changed: Recruiting → Active, Not Recruiting
    • Primary and study completion moved earlier from Mar 1, 2027 to Sep 16, 2026
    • Study sites: 53 to 54
    v5
  5. Study sites: 22 to 53v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date changed from estimate of Dec 6, 2025 to Dec 5, 2025
    • Eligibility criteria revised
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary endpoint revised
    • Study sites: 1 to 22
    • Start date: Dec 1, 2025 to Dec 6, 2025
    • Secondary endpoints revised (10)
    • Study description revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a randomized, double-blind, placebo-controlled clinical trial. Investigators aim to assess the efficacy and safety of interleukin-6 receptor inhibitor combined with endovascular treatment in patients with acute anterior circulation large vessel occlusion stroke.
Trial Details
NCT Number NCT07263776
Lead Sponsor Capital Medical University
Conditions
(from sponsor)		 Acute Ischemic Stroke
Related terms Ischemic Stroke, Stroke
Enrollment 692 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov